NCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
BeiGene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eli Lilly and Company
Takeda